Brain and Behavior (Jul 2023)

Dopamine transporter binding in the brain is linked to irritable bowel syndrome in Parkinson's disease

  • Kirsi Murtomäki,
  • Juho Joutsa,
  • Tuomas Mertsalmi,
  • Elina Jaakkola,
  • Elina Mäkinen,
  • Reeta Levo,
  • Mikael Eklund,
  • Simo Nuuttila,
  • Eero Pekkonen,
  • Tommi Noponen,
  • Toni Ihalainen,
  • Valtteri Kaasinen,
  • Filip Scheperjans

DOI
https://doi.org/10.1002/brb3.3097
Journal volume & issue
Vol. 13, no. 7
pp. n/a – n/a

Abstract

Read online

Abstract Background Gastrointestinal symptoms are common in Parkinson's disease (PD), but their neurophysiological correlates are not well understood. We recently reported that functional gastrointestinal symptoms were not associated with asymmetry per se but might be associated with lower left striatal dopamine transporter (DAT) binding. The purpose of this study was to further investigate if specific gastrointestinal symptoms associate with monoamine transporter changes in specific striatal or extrastriatal areas. Methods Ninety PD patients, who underwent DAT ¹23I‐FP‐CIT SPECT imaging, were assessed using the MDS‐Unified Parkinson's Disease Rating Scale part III, Rome III, and Wexner constipation score. DAT binding was calculated from striatal subregions using region‐to‐occipital cortex ratio. Voxel‐wise analysis was used to assess the relationship between gastrointestinal symptoms and striatal DAT and extrastriatal serotonin transporter (SERT) binding. Results Irritable bowel syndrome (IBS) criteria were fulfilled in 17 patients and were linked to higher ¹23I‐FP‐CIT binding in the right posterior putamen and adjacent areas as compared to patients without IBS. No other significant associations between gastrointestinal symptoms and DAT or SERT binding were found. Conclusions These findings suggest that PD patients with IBS may have higher DAT binding in the right hemisphere. This finding implicates alterations of brain neurotransmitter physiology in the gastrointestinal symptoms of PD patients.

Keywords